- Home
- TFPM vs PTGX Comparison
TFPM vs PTGX Comparison
Compare TFPM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TFPM | PTGX |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.0B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | TFPM | PTGX |
|---|---|---|
| Price | $32.37 | $86.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $32.33 | ★ $86.44 |
| AVG Volume (30 Days) | 532.0K | ★ 862.5K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.01 | 0.72 |
| Revenue | ★ $344,001,000.00 | $209,217,000.00 |
| Revenue This Year | $42.63 | N/A |
| Revenue Next Year | $11.85 | $296.47 |
| P/E Ratio | ★ $32.15 | $119.45 |
| Revenue Growth | ★ 39.55 | N/A |
| 52 Week Low | $14.51 | $33.70 |
| 52 Week High | $34.50 | $93.25 |
Technical Indicators
Market Signals| Indicator | TFPM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 58.15 |
| Support Level | $31.85 | $83.52 |
| Resistance Level | $34.50 | $90.85 |
| Average True Range (ATR) | 1.19 | 2.71 |
| MACD | 0.23 | -0.48 |
| Stochastic Oscillator | 61.27 | 45.51 |
Price Performance
Historical ComparisonAbout TFPM Triple Flag Precious Metals Corp.
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.